

1 **The Alaska Native/American Indian experience of hepatitis C treatment with**
2 **sofosbuvir-based direct-acting antivirals**

3

4 Lisa Townshend-Bulson¹, Elena Roik¹, Youssef Barbour¹, Dana Bruden², Chriss Homan¹,
5 Hannah Espera¹, Tim Stevenson³, Annette Hewitt¹, Wileina Rhodes¹, Jim Gove¹, Julia Plotnik¹,
6 Mary Snowball¹, John McGilvray⁴, Brenna C. Simons², Brian McMahan¹

7

8 **Full affiliations**

9 ¹Alaska Native Tribal Health Consortium, Liver Disease and Hepatitis Program, Anchorage,
10 Alaska, USA

11 ²Centers for Disease Control and Prevention, Anchorage, Alaska, USA

12 ³Alaska State Virology Laboratory, Anchorage, Alaska, USA

13 ⁴Southcentral Foundation, Pharmacy Department, Anchorage, Alaska, USA

14

15 **Corresponding author:**

16 E-mail: ltownshend@anthc.org

17

18

19

20

21

22

23

24 **Abstract**

25 **Background.** Direct-acting antiviral (DAA) drugs have been effective in the treatment of
26 chronic hepatitis C virus (HCV) infection. Limited data are available on safety, tolerability, and
27 efficacy in American Indian or Alaska Native people. We aim to evaluate the treatment
28 outcomes of sofosbuvir- based regimens for treatment of HCV in a real life setting in Alaska
29 Native/American Indian (AN/AI) people.

30 **Methods.** AN/AI patients within the Alaska Tribal Health System with confirmed
31 positive anti-HCV and HCV RNA, who were 18 years of age and older were included in the
32 study. Pretreatment baseline patient characteristics, treatment efficacy based on sustained
33 virologic response (SVR) 12 weeks after treatment completion, and adverse effects were
34 assessed. The following treatments were given according to the American Association for the
35 Study of Liver Diseases/Infectious Disease Society of America (AASLD/IDSA) HCV Guidance:
36 ledipasvir/sofosbuvir, sofosbuvir plus weight-based ribavirin, and sofosbuvir/velpatasvir.

37 **Results.** We included 501 patients with a mean age of 54.3 (range 21.3 -78.3) in the
38 study. Overall SVR was achieved in 95.2% of patients who received one of the three DAA
39 regimens. For those with cirrhosis, overall SVR was 92.8% and for those with genotype 3 91.1%
40 achieved SVR. The most common symptom experienced during treatment was headache. Joint
41 pain was found to decrease during treatment. One person discontinued sofosbuvir plus ribavirin
42 due to myocardial infarction and one discontinued sofosbuvir/velpatasvir due to urticaria.

43 **Conclusions.** In the real-world setting, sofosbuvir-based treatment is safe, effective, and
44 well tolerated in AN/AI patients. Sustained virologic response was high regardless of HCV
45 genotype or cirrhosis status.

46 **Keywords** Chronic hepatitis C, Alaska Native, direct acting antiviral agents, sofosbuvir,
47 sustained virologic response, adverse effect, AN/AI

48 **Introduction**

49 Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease and
50 liver-related death worldwide (1, 2). The number of chronically infected individuals globally is
51 estimated to be over 130 million (3). Moreover, most new cases of acute HCV infection are not
52 identified or reported to public health authorities because most adults and adolescents with HCV
53 do not have symptoms and are unaware of their infection (4). The U.S. Centers for Disease
54 Control and Prevention (CDC) estimates there were 41,200 new HCV infections in the United
55 States in 2016 alone (4). Chronic hepatitis C is a known risk factor for development of
56 hepatocellular carcinoma (HCC) (5). Out of 700,000 cases of HCC that occurred worldwide in
57 2008, 17 to 22% are attributable to HCV infection (6, 7).

58 The prevalence of HCV infection in the United States in 2013-2016 was reported to be
59 2.4 million cases, with over 30,000 new cases of HCC and approximately 27,000 deaths
60 registered every year (8, 9). The implementation of extended criteria for Hepatitis C screening is
61 a subject of major policy debate underscoring the rising concerns over the growing public health
62 and economic burden of HCV infection (10, 11). The first National Viral Hepatitis Action Plan
63 that aimed to eliminate hepatitis C was issued in 2011(12). It focused on hepatitis B and C
64 elimination by the year 2020 and recognized that success of the action plan could not be
65 achieved without input from non-federal stakeholders, both public and private. Since then,
66 several U.S. states implemented their own hepatitis elimination programs with ambitious goals of
67 eliminating viral hepatitis by 2030, in accordance with the World Health Organization's directive
68 on eliminating viral hepatitis (13, 14).

69 A number of studies have described the epidemiology of HCV infection among American
70 Indian or Alaska Native people (15-20). Risk factors for acquisition of HCV infection and
71 genotype (GT) distribution among AN/AI were similar to those found in the National Health and
72 Nutritional Examination Survey (17, 18). End stage liver disease (ESLD) was associated with
73 older age and alcohol usage (20). Previously we found that AN/AI people did not respond well
74 to peginterferon and ribavirin-based treatment with an overall (all GTs) SVR rate of 51% and
75 discontinuation rate of 52% (19). Genotype 3 HCV infection was associated with a high risk for
76 developing ESLD, HCC and liver-related death (18). Bruden et al (20) emphasized the need for

77 early hepatitis C treatment of patients with moderate fibrosis to prevent development of ESLD,
78 HCC and liver-related death over time.

79 Alaska Native and American Indian (AN/AI) communities are one of the priority
80 populations in the National Viral Hepatitis Elimination Plan (21). A recent study showed that
81 86% of AN/AI people diagnosed with HCV infection in Alaska were linked to care and
82 treatment in 2017 (16). Despite that, national data show AN/AI people are disproportionately
83 affected by hepatitis C with the highest rates of both acute HCV infection and hepatitis C-related
84 deaths (21).

85 With the advent of new direct-acting antivirals (DAAs) the HCV treatment landscape has
86 changed. Recent studies report higher efficacy, shorter treatment duration, and fewer side effects
87 with the inclusion of the DAA sofosbuvir into treatment regimens (22-24). Importantly, hepatitis
88 C DAA therapy has eliminated the GT dependent differences in effectiveness that were
89 associated with interferon-based therapies. Public health experts now believe it is possible to
90 eliminate the disease. Hepatitis C elimination could have a tremendous positive effect on
91 improving health outcomes by preventing around 400,000 deaths worldwide from complications
92 each year (25).

93 There is ongoing discussion about whether the effectiveness of hepatitis C treatment
94 varies between racial and ethnic groups in the United States. The Liver Disease and Hepatitis
95 program (LDHP) at the Alaska Native Tribal Health Consortium (ANTHC) provides a reliable
96 setting to study disparities in hepatitis C treatment due to high rates of the disease in Alaska (26),
97 with an ongoing registry in place, and an established AN/AI HCV-infected cohort from a large
98 and diverse AN/AI population.

99 In this study we aimed to evaluate the effectiveness of sofosbuvir-based hepatitis C
100 treatment regimens and describe any differences in experience and outcome among AN/AI
101 people living in Alaska as compared to other racial and ethnic groups.

102

103 **Materials and Methods**

104 **Study design, setting, participants and data collection**

105

106 In 1995, the ANTHC LDHP began a hepatitis C population-based cohort study (AK-
107 HEPC) to learn more about adverse outcomes of chronic HCV infection in AN/AI persons.
108 AN/AI persons residing in Alaska can receive care through the Alaska Tribal Health System
109 (ATHS), an integrated system of tribally-owned and operated health care organizations for which
110 ANTHC is the umbrella organization coordinating healthcare throughout the ATHS. The LDHP
111 operates out of the Alaska Native Medical Center (ANMC), the specialty referral hospital for the
112 ATHS located in Anchorage, Alaska. Statewide testing for HCV infection is provided at ANMC
113 for AN/AI people. All persons found to be HCV antibody (anti-HCV) positive are entered into a
114 registry for clinical care. New positive anti-HCV tests are automatically reflexed to HCV RNA
115 testing when specimen quantity permits. Those entered into the registry are invited to join the
116 AK-HEPC cohort study. Sofosbuvir-based treatment for this cohort was studied from March 1,
117 2014 through September 30, 2019 in 501 patients with chronic HCV.

118 AN/AI patients within ATHS with confirmed positive anti-HCV and HCV RNA, who
119 were 18 years of age and older, and who provided written informed consent were included in the
120 study. The study was approved by the Alaska Area Institutional Review Board and by two
121 Alaska Tribal Health Organizations, ANTHC and Southcentral Foundation.

122 Patients were excluded from the study if they had negative HCV RNA prior to treatment,
123 current incarceration, contraindication to taking any component of a sofosbuvir-based regimen,
124 or no indication for treatment in accordance with the American Association for the Study of
125 Liver Diseases (AASLD) and Infectious Disease Society of America (IDSA) HCV Guidance
126 (27).

127 **Ethical Considerations**

128 Hepatitis C treatment options were discussed with the patient prior to consenting to the
129 treatment study. These options included all available hepatitis C medications, not just
130 sofosbuvir-based drugs. This manuscript examines hepatitis C treatment and outcomes of
131 patients who were treated with sofosbuvir-based drugs only.

132 AUDIT-C alcohol screening and PHQ-9 depression screening tests were completed by
133 patients prior to treatment start. Those with positive AUDIT-C scores (≥ 3 for women and ≥ 4
134 for men) were counseled about hazardous drinking and offered referral to a behavioral health
135 counselor.

136

137 **Treatment Regimens**

138 The Food and Drug Administration-approved sofosbuvir-based treatment regimens
139 included in this study were ledipasvir/sofosbuvir, sofosbuvir plus weight-based ribavirin, and
140 sofosbuvir/velpatasvir. Indications and treatment duration in accordance with prescribing
141 information are shown in Table 1.

142 Due to low numbers for comparison, those with decompensated cirrhosis treated with
143 sofosbuvir/velpatasvir for 24 weeks (n=1), ledipasvir/sofosbuvir for 24 weeks (n=17),
144 sofosbuvir/velpatasvir with ribavirin for 12 weeks (n=6), ledipasvir/sofosbuvir and ribavirin for
145 12 weeks (n=9), and ledipasvir/sofosbuvir and ribavirin for 24 weeks (n=4) were not included in
146 this analysis.

147
148 Treatment protocol was the same for those who were enrolled in the study cohort and
149 those who chose not to be in the study and based on current recommendations from the
150 AASLD/IDSA HCV Practice Guidance (27). For those participants treated at other mostly rural
151 Alaska Tribal facilities, the same treatment protocol was followed except there was not a
152 requirement to complete a symptoms inventory before and during treatment. For participants
153 treated at other Alaska Tribal facilities, LDHP providers were consulted by rural tribal providers
154 for treatment recommendations.

155 **Study Assessments**

156 Pretreatment baseline characteristics (Table 2) and laboratory results [including:
157 complete blood count (CBC), comprehensive metabolic panel (CMP), prothrombin time with
158 international normalized ratio, HCV RNA, HCV GT, alpha fetoprotein, vitamin D, glycosylated
159 hemoglobin (HgbA1C), human immunodeficiency virus (HIV), hepatitis B core antibody (anti-
160 HBc), hepatitis B surface antigen (HBsAg), hepatitis A antibody total, IL-28b genotype, and
161 pregnancy test [for women of childbearing age] were assessed. HBV DNA testing was done for
162 those who were found to be anti-HBc positive. Those who were not immune or previously
163 vaccinated for hepatitis A and B were offered the appropriate vaccine series.

164 Liver fibrosis was assessed by either vibration controlled transient elastography (VCTE)
165 using FibroScan[®], serum fibrosis test, or liver biopsy. A pre-treatment VCTE was performed on
166 all patients who were treated through the ANTHC LDHP, except for the first 7 who had begun

167 treatment prior to availability of VCTE at ANTHC. Fibrosis stage was assessed according to
168 Metavir-equivalent scoring (F0 to F4). Median VCTE level ≥ 12 kPa was defined as cirrhosis.

169 A thorough health history was completed prior to treatment. This included presence or
170 history of the following: any liver disease or cirrhosis; pulmonary disorders; cardiovascular
171 disease; including deep vein thrombosis and pulmonary embolism; use of acid-reducing agents
172 including proton pump inhibitors (PPIs), H2 blockers and antacids; autoimmune disorders; organ
173 transplant; cancer; current infection; high blood pressure; dyslipidemia; kidney disease; anemia;
174 current TB treatment; diabetes Type 1 or 2; HIV; seizure disorder; and mental health conditions.
175 A complete medication history, which included both prescription and over-the-counter
176 supplements, was obtained to identify any potential interactions with sofosbuvir-based drugs.
177 Participants' vaccine status for influenza, pneumonia, tetanus and Tdap, and shingles were
178 reviewed and those who were not up-to-date on those vaccines were offered them.

179 The safety and tolerability of antiviral drug regimens were assessed by reviewing the
180 answers on the baseline self-reported symptoms inventory completed prior to treatment and
181 subsequent symptoms inventories which were completed monthly through the end of treatment,
182 to assess for potential adverse effects related to HCV treatment. Symptoms included in the
183 inventory were: feeling excessively tired (fatigue), flu-like illness, chills, fever, weakness,
184 trouble sleeping, headache, hair loss, dry mouth, cough, shortness of breath, decreased appetite,
185 nausea, vomiting, weight loss, heartburn or upset/sour stomach, muscle aches, joint aches, back
186 pain, itching, rash, dizziness, irritability, depression or anxiety, changes in mood/mood swings,
187 and feeling forgetful/problems concentrating.

188 Prior to treatment start, an HCV treatment agreement was signed by the patient which
189 explained the treatment process, possible side effects, drug interactions, expected efficacy, and
190 asked the patient to agree to the following:

- 191 • Not to drink alcohol or use recreational drugs during treatment.
- 192 • Report any serious medical conditions, including heart disease, high blood pressure,
193 diabetes, high cholesterol, rheumatoid arthritis, drug addiction, or psychiatric condition.
- 194 • Commit to taking medications as prescribed and if unable to do so to contact provider.
- 195 • Protect self and others from hepatitis C by not sharing needles, drug works, razors,
196 toothbrushes, or nail clippers, and cover cuts to prevent blood exposure.

197 Patients were not penalized if they broke the agreement but were encouraged to resume
198 adherence to it. If a patient identified as having a substance use disorder, referral to behavioral
199 health was offered.

200 Labs obtained monthly during treatment and analyzed included: HCV RNA, CBC, CMP,
201 HBV DNA (if HBsAg positive or if HBV DNA present in those who were anti-HBc positive
202 prior to treatment), and pregnancy test on women of childbearing age.

203 Treatment completion or discontinuation of medications was documented. Treatment
204 efficacy as determined by sustained virologic response (SVR) 12 weeks after treatment
205 completion was assessed using HCV RNA (COBAS(R) AmpliPrep /COBAS(R) TaqMan(R)
206 HCV Test Kit (Roche Molecular Systems, Inc., Pleasanton, CA). CBC, hepatic function panel
207 and AFP were drawn at SVR time point and VCTE was repeated to assess liver fibrosis at that
208 time.

209 One year after treatment completion, VCTE was repeated to reassess liver fibrosis.
210 All patients whose pre-treatment fibrosis assessment (either by VCTE, serum fibrosis test, or
211 liver biopsy) indicated advanced liver fibrosis (Metavir F3-F4 equivalent fibrosis) were
212 instructed to continue to have right upper quadrant (RUQ) ultrasound along with AFP blood test
213 every 6 months as surveillance for HCC.

214

215 **Data Analysis**

216 For the outcome of DAA treatment success rate, we calculated SVR in an intention-to-
217 treat analysis and a per-protocol analysis. The intention-to-treat analysis included all persons
218 who started HCV treatment. The per-protocol analysis removed persons who discontinued
219 treatment early, regardless of their virologic response and persons who were lost to follow-up
220 with an unknown virologic response. We compared the SVR rate using a likelihood ratio χ^2 or
221 Cochran-Armitage test of trend. The high SVR rates with an associated low sample size of
222 treatment failures limited the building of multivariable logistic regression models. We used
223 forward selection with log-binomial regression. After inclusion of the most significant
224 univariate variable, no statistically significant multivariable models were found. We compared
225 alanine aminotransferase (ALT), AFP and VCTE results before and after treatment using a
226 normal or log-normal response and generalized estimating equations were used to account for
227 repeated measurements. The prevalence of side effects reported on the symptoms inventory was

228 compared between the start and end of treatment using generalized estimating equations logistic
229 regression. We used the start of treatment as the start of follow-up and the date of HCC
230 detection, death date, or Dec 1, 2019 as the end of follow-up for calculating HCC incidence
231 following treatment. Exact *P*-values were reported when sample size necessitated. All analyses
232 were run in SAS version 9.4 and a *P*-value < 0.05 was considered statistically significant.

233

234 **Results**

235

236 **Characteristics of study participants**

237 Characteristics of patients at baseline are shown in Table 2. The final data analysis
238 occurred on 501 AN/AI persons who received *sofosbuvir*-based treatment from 2014 to 2018.
239 Seventy-five percent of treatments were prescribed by ANTHC LDHP providers on the ANMC
240 campus in Anchorage; (n=378); 25% were prescribed by providers at other Alaska Tribal
241 facilities, following the protocol used at ANTHC LDHP except symptoms inventory was limited
242 to participants treated in Anchorage.

243 For comparison, study participants were divided into three groups based on the treatment
244 regimen: ledipasvir/sofosbuvir, sofosbuvir plus ribavirin, and sofosbuvir/velpatasvir.
245 Sofosbuvir-based treatment type and duration of treatment were determined by HCV GT, and
246 fibrosis status in accordance with AASLD/IDSA treatment guidance available at the time of
247 treatment (27).

248 Median age of study participants was 54.3 years, ranging from 21.3 to 78.3. The majority
249 of patients were GT-1a [327 (65%)]; male [272(54%)], and treatment naïve [474(95%)]. The
250 mean body mass index (BMI) was 28.0; 122/417 (29%) patients had a BMI greater than 30.
251 Advanced fibrosis occurred in 134/497 (27%) persons and 69/497 (14%) patients had cirrhosis
252 (F4). HCV RNA greater than six million international units/ml was observed in 92/501 (18%)
253 patients.

254 Of the 501 persons, 480 (96%) completed their treatment regimen. Twenty percent
255 (93/460) of persons were anti-HBc positive prior to sofosbuvir-based treatment; with 4 of those
256 having chronic hepatitis B (HBsAg positive). Four participants who reported ongoing injection
257 drug use had achieved SVR and then had HCV RNA detected at a later time point, suggesting

258 reinfection. Eight patients (2%) were HIV positive. There were no positive pregnancy tests
259 during the study.

260

261 **Therapeutic Response for Sofosbuvir-based Treatment in AN/AI** 262 **People**

263 Sofosbuvir-based medication consisted of ledipasvir/sofosbuvir (n=348),
264 sofosbuvir/velpatasvir (n=94), and sofosbuvir plusribavirin (n=59). The most frequent treatment
265 length was 12 weeks (74%), followed by 8 weeks (22%), 24 weeks (3%), and 16 weeks (1%).
266 SVR was analyzed for both intention-to-treat and per-protocol groups in Table 3.

267 First, we looked at SVR in the intention-to-treat analysis. Overall SVR rate for
268 sofosbuvir-based treatment was 95.2% (477/501); for the patients treated at ANMC, SVR was
269 95.8% versus 93.5% at other Alaska locations. This was not statistically significant. Females did
270 not differ in treatment success compared with males ($P=0.09$). Patients who completed treatment
271 had significantly higher treatment success compared to those who did not finish treatment
272 ($P<0.0001$). Those with cirrhosis responded as well to treatment as those without cirrhosis.
273 Additionally, there were no significant differences in treatment success by age, HCV GT, IL-28b
274 GT, use of acid-reducing agent, anti-HBc positive status, or having undergone a previous HCV
275 treatment.

276 We next looked at SVR per-protocol (removing those who discontinued treatment and
277 persons lost to follow up following treatment completion). These exclusion criteria reduced the
278 analysis cohort to 479 persons. Overall treatment success improved to 97.3% (466/479). SVR
279 was significantly higher for patients treated at ANMC compared to other Alaska locations
280 ($P=0.02$). Fibrosis level at treatment start became significant to treatment success ($p<0.01$) in the
281 per-protocol analysis. Age, sex, HCV GT, IL-28b status, or acid-reducing agent use remained
282 non-significant. Higher SVR rate of those without presence of cirrhosis was significant
283 ($P=0.002$) as compared to those with compensated cirrhosis. Also, those who had not undergone
284 previous HCV treatment had a significantly higher SVR rate ($P=0.03$) compared to those who
285 had been previously treated.

286 Eleven persons developed HCC after their treatment (range of 3 months to 3.7 years after
287 treatment); all had F3 to F4 fibrosis prior to treatment. HCC incidence following DAA treatment
288 was 6.37 cases per 1000 person-years of follow-up.

289 There were four HCV re-infections (<1%) that occurred in participants who had achieved
290 SVR. All four were found to have a different GT, and had known continued injection drug use.
291 Having resolved hepatitis B infection, isolated anti-HBc positive, or chronic hepatitis B (HBsAg-
292 positive) did not affect SVR rate in our AN/AI cohort. Also, there were no flares of hepatitis B
293 (defined as elevated ALT >2 ULN and HBV DNA > 2,000 IU/mL in persons with previously
294 inactive or resolved HBV) among those who were anti-HBc+ (28), including those with chronic
295 hepatitis B during treatment. There was one death while on HCV treatment due to non-liver
296 related cancer, and two deaths of unknown cause following HCV treatment completion but prior
297 to SVR time point.

298

299 ***Changes in Treatment Characteristics from Pre to Post Treatment***

300 We investigated changes in ALT, AFP, and VCTE fibrosis score pre to post treatment for
301 those at ANMC only. All characteristics explored were significant regardless of SVR (Table 4).
302 Treatment success led to reduced AFP levels post treatment and significant reductions in fibrosis
303 scores by VCTE 1-2 years after treatment.

304

305 ***Side Effects***

306 Changes in the prevalence of adverse effects, collected through the symptoms inventory,
307 between week 0 and the end of treatment, were analyzed by treatment regimen from the patients
308 treated at ANMC (Table 5). Persons who received sofosbuvir plus ribavirin experienced an
309 increase in mood changes ($P=0.040$), shortness of breath ($P=0.003$), and dizziness ($P=0.040$).
310 Those who received ledipasvir/sofosbuvir reported only an increase in headache ($P=0.004$) on
311 treatment, and those who received sofosbuvir/velpatasvir did not show any statistically
312 significant increases in symptoms during treatment. There was one person who discontinued
313 treatment after one day taking sofosbuvir/velpatasvir because of urticaria. One person
314 discontinued sofosbuvir plus ribavirin after hospitalization for non-ST segment elevation
315 myocardial infarction secondary to coronary vasospasm.

316 Conversely, after SVR there was a reported significant decrease in joint pain by
317 participants receiving any of the three regimens. Those who received sofosbuvir + ribavirin and
318 ledipasvir/sofosbuvir reported a significant decrease in back pain. Those who received
319 sofosbuvir/velpatasvir reported less depression ($P=0.02$) and less decreased appetite ($P<0.01$).
320 Additionally, those who were treated with ledipasvir/sofosbuvir regimens reported significant
321 decreases in trouble sleeping ($P= 0.020$), joint pain ($P=0.001$), back pain ($P=0.002$), and muscle
322 pain ($P=0.040$).

323

324 **Discussion**

325 In this sofosbuvir-based treatment study of AN/AI patients with HCV, overall SVR was
326 achieved by 95.2% of participants. These SVR rates are comparable to rates found in other
327 ethnic groups (29, 30). There were no statistically significant differences in SVR rate by HCV
328 GT, IL-28 GT, or acid blocker use. Sofosbuvir-based HCV treatment regimens were effective
329 and tolerated well by AN/AI persons.

330 The introduction of all-oral sofosbuvir therapeutic regimens for the treatment of chronic
331 hepatitis C has led to remarkable improvement in SVR, providing therapeutic options to patients
332 with contraindications to IFN-based regimens as well as those who either failed or were
333 intolerant to IFN. However, despite the more convenient dosing schedules and shorter durations
334 of treatment and high cure rates, a small percentage of patients experience treatment failure. The
335 SVR results of our study are in line with earlier studies reporting SVR rates between 87% and
336 99% (29, 31-34). Furthermore, 92.8% of patients with compensated cirrhosis achieved SVR. The
337 SVR rate for cirrhosis patients achieved in our study is similar to those reported in phase 2 and 3
338 clinical trials (35, 36).

339 We assume the high SVR rate of 97.3% in those who completed the study per-protocol
340 was achieved due to high adherence rate and close monitoring and follow-up by experienced
341 nurses and health care providers.

342 In our study the decreases in non-invasive serological markers (ALT, AFP) and VCTE
343 fibrosis scores suggest a significant regression of inflammation and liver fibrosis in patients at
344 SVR12 as compared to baseline. Several studies have shown the same results; however, the
345 effect was more pronounced in patients with baseline VCTE scores suggesting advanced stages

346 of fibrosis and cirrhosis (37, 38). However, the findings of decreases in liver stiffness scores
347 might be influenced by inflammation, resulting in lower kPa measurements after SVR, which has
348 been previously found in patients with chronic hepatitis (39).

349 Hepatitis due to reactivation of HBV infection during treatment with DAAs for chronic
350 HCV infection has been reported in patients who were anti-HBc+ prior to treatment. In general,
351 an HBV flare is defined as elevated ALT and HBV DNA > 2,000 IU/mL in persons with
352 previously inactive or resolved HBV infection. Findings from Loggi et al. (40) on 44 subjects
353 who received DAA treatment for HCV infection, found no reactivation in those with past HBV
354 infection (anti-HBc+ only). They also found that two persons who were HBsAg-positive
355 experienced a flare of HBV infection, followed by HBsAg loss. Another study showed that
356 hepatitis B reactivation was a rare event in anti-HBc+/HBsAg-negative patients treated with
357 DAA therapy (41). In our study there were a large number of anti-HBc+ patients (93). Eighty
358 nine of these patients were anti-HBc+/HBsAg-negative whom we assume were infected with
359 hepatitis B and recovered shortly after, and 4 patients were HBsAg-positive, having chronic
360 hepatitis B coinfection. None of these 93 patients experienced flares of HBV during or
361 immediately following treatment. This finding adds support to the body of knowledge showing
362 hepatitis B flares, among those chronically infected and reactivation among those with resolved
363 infection, as a result of HCV treatment, is rare.

364 HCV reinfection following successful treatment can compromise treatment outcomes. In
365 our study population, we observed less than 1 percent reinfection rate due to ongoing drug use in
366 those who achieved SVR during the span of the study follow up period. A recent meta-analysis
367 showed an overall rate of HCV reinfection of 5.9/100 person-years (95% CI 4.1-8.5) among
368 people with recent drug use (injecting or non-injecting), and 6.2/100 person-years (95% CI 4.3-
369 9.0) among people recently injecting drugs (42).

370 In our study none of the participants experienced serious adverse effects. The symptoms
371 that increased in frequency were: headache for *ledipasvir/sofosbuvir*, and changes in mood,
372 shortness of breath, and dizziness on *sofosbuvir* plus *ribavirin*, which is likely due to ribavirin.
373 That is in line with previous studies (36, 43-45). Mizokami et al (46) data shows that the most
374 common adverse effects on sofosbuvir-based treatment are nasopharyngitis, anemia, headache
375 and malaise. Difference in the results may be partially explained by the differences in inherent
376 metabolic pathways and different drug-drug interactions.

377 Our study adds to the body of evidence regarding successful hepatitis C treatment among
378 racial minorities, specifically AN/AI people. It is the largest study to date of American Indian or
379 Alaska Native persons with hepatitis C treated with DAAs (47).

380 Limitations of our study are that the cohort includes only AN/AI persons, therefore our
381 findings may not apply to other racial/ethnic groups. However, this cohort was described
382 previously and found to closely represent the US population infected with HCV in terms of HCV
383 GT distribution and risk factors for infection (17).

384 Treatment of HCV infection does not only benefit those infected but also reduces the
385 burden of hepatitis C at the population level (2). Regardless of stage of liver disease, coinfection,
386 or complications there is a survival benefit of SVR (2). Cure of HCV infection has a long term
387 impact on the economic burden of disease (48). Complications of HCV infection such as liver
388 cirrhosis, HCC and transplantation are associated with high medical cost and use of healthcare
389 resources (49). From a public health perspective, the “treatment as prevention” model as
390 undertaken by ANTHC LDHP is of great benefit. It may reduce the prevalence of HCV
391 infection in the population in the long-term, leading to a lower transmission rate and incidence of
392 disease. To achieve 2030 targets of a 90% reduction in new cases of HCV infection and a 65%
393 reduction in liver-related death, a new capacity for screening and treatment should be built.
394 Hepatitis C needs to become a disease of high priority in both clinical and public health settings.

395

396 **Conclusion**

397 Our treatment study with sofosbuvir-based regimens was effective for a broad range of
398 AN/AI patients with HCV GT 1, 2, 3, 4, or 6 infection. The treatment was also effective among
399 patients with cirrhosis. These real-life study findings, in a population not included in pre-
400 licensure clinical trials, suggest that HCV treatment for AN/AI persons should lead to a long-
401 term decrease in liver disease progression and prevention of the development of HCC and
402 reduction in disparities of HCV liver disease for AN/AI people.

403 To date, over 1000 AN/AI persons in Alaska have been treated through the ATHS and
404 cured of hepatitis C with DAA therapy. However, there remains another 1000 known AN/AI
405 persons in Alaska with hepatitis C including approximately 180 AN/AI persons living in over
406 100 isolated communities without primary care providers and not connected to the road system.

407 Moving forward, the use of telemedicine and other innovative ways to test and treat HCV are
408 being explored so that all AN/AI people can access antiviral treatment, disparities in liver disease
409 outcomes can lessen, and the overarching goal of HCV elimination can be met in the AN/AI
410 population.

411

412 **Conflict of Interest**

413 This study was funded in part by Gilead Sciences.

414

415 **Disclaimer**

416 Dana Bruden is employed by the CDC. The findings and conclusions in this study are those of
417 the authors and do not necessarily represent the official position of the CDC.

418

419

420

421

422

423

424

425

426 References

- 427 1. Lavanchy D. Evolving epidemiology of hepatitis C virus. *Clin Microbiol Infect.* 2011;17(2):107-15.
- 428 2. WHO. Global Hepatitis Report 2017 [Available from:
429 [https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-](https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=57E13E6157F27DF0909272374DB84FAA?sequence=1)
430 [eng.pdf;jsessionid=57E13E6157F27DF0909272374DB84FAA?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=57E13E6157F27DF0909272374DB84FAA?sequence=1).
- 431 3. Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A
432 global view. *World J Hepatol.* 2015;7(26):2676-80.
- 433 4. CDC. Surveillance for Viral Hepatitis – United States, 2016 2016 [Available from:
434 <https://www.cdc.gov/hepatitis/statistics/2016surveillance/commentary.htm>.
- 435 5. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology.*
436 2012;142(6):1264-73 e1.
- 437 6. WHO. Liver Cancer. Keyfacts. 2008 [Available from:
438 <https://www.who.int/cancer/resources/keyfacts/en/>.
- 439 7. WHO. Liver Cancer. 2018 [Available from: [https://www.who.int/hepatitis/news-events/world-](https://www.who.int/hepatitis/news-events/world-cancer-day/en/)
440 [cancer-day/en/](https://www.who.int/hepatitis/news-events/world-cancer-day/en/).
- 441 8. Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, et al. Estimating
442 Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. *Hepatology.* 2019;69(3):1020-
443 31.
- 444 9. CDC. Liver cancer. Facts. 2019 [Available from: <https://www.cdc.gov/cancer/liver/index.htm>.
- 445 10. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis
446 C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. *Gastroenterology.*
447 2016;150(7):1599-608.
- 448 11. Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, et al. The impact of hepatitis C virus
449 outside the liver: Evidence from Asia. *Liver Int.* 2017;37(2):159-72.
- 450 12. HHS. National Viral Hepatitis Action Plan 2011. 2011 [Available from:
451 <https://www.hhs.gov/sites/default/files/action-plan-viral-hepatitis-2011.pdf>.
- 452 13. Department of Health WS. Plan to Eliminate Hepatitis C in Washington State by 2030 2019
453 [Available from: [https://www.doh.wa.gov/Portals/1/Documents/Pubs/150nonDOH-HepCFreeWA-](https://www.doh.wa.gov/Portals/1/Documents/Pubs/150nonDOH-HepCFreeWA-PlanJuly2019.pdf)
454 [PlanJuly2019.pdf](https://www.doh.wa.gov/Portals/1/Documents/Pubs/150nonDOH-HepCFreeWA-PlanJuly2019.pdf).
- 455 14. Department of Health NYS. New York State Hepatitis C Elimination Task Force 2019 [Available
456 from: https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/elimination.htm.
- 457 15. McMahon BJ, Bruden D, Bruce MG, Livingston S, Christensen C, Homan C, et al. Adverse
458 outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. *Gastroenterology.*
459 2010;138(3):922-31 e1.
- 460 16. McMahon BJ, Townshend-Bulson L, Homan C, Gounder P, Barbour Y, Hewitt A, et al. Cascade of
461 Care for Alaska Native People with Chronic Hepatitis C Virus Infection: Statewide Program with High
462 Linkage to Care. *Clin Infect Dis.* 2019.
- 463 17. McMahon BJ, Hennessy TW, Christensen C, Bruden D, Sullivan DG, Homan C, et al. Epidemiology
464 and risk factors for hepatitis C in Alaska Natives. *Hepatology.* 2004;39(2):325-32.
- 465 18. McMahon BJ, Bruden D, Townshend-Bulson L, Simons B, Spradling P, Livingston S, et al. Infection
466 With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease,
467 Hepatocellular Carcinoma, and Liver-Related Death. *Clin Gastroenterol Hepatol.* 2017;15(3):431-7 e2.
- 468 19. Livingston SE, Townshend-Bulson LJ, Bruden DJ, Homan CE, Gove JE, Plotnik JN, et al. Results of
469 interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.
470 *Int J Circumpolar Health.* 2016;75:30696.

- 471 20. Bruden DJT, McMahon BJ, Townshend-Bulson L, Gounder P, Gove J, Plotnik J, et al. Risk of end-
472 stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C
473 Alaska Cohort. *Hepatology*. 2017;66(1):37-45.
- 474 21. HHS. National Viral Hepatitis Plan 2017-2020. 2017 [Available from:
475 <https://www.hhs.gov/hepatitis/action-plan/national-viral-hepatitis-action-plan-overview/index.html>.
- 476 22. Gentile I, Borgia F, Zappulo E, Buonomo AR, Spera AM, Castaldo G, et al. Efficacy and Safety of
477 Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era. *Rev Recent Clin Trials*.
478 2014;9(1):1-7.
- 479 23. Afdhal NH. A Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Hepatitis C Virus
480 Genotype 1. *Gastroenterol Hepatol (N Y)*. 2014;10(12):815-7.
- 481 24. Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, Orkin C, et al. Sofosbuvir and
482 Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The
483 Impact on Patient-Reported Outcomes. *J Infect Dis*. 2015;212(3):367-77.
- 484 25. WHO. Hepatitis C. Key Facts. 2019 [Available from: [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/hepatitis-c)
485 [sheets/detail/hepatitis-c](https://www.who.int/news-room/fact-sheets/detail/hepatitis-c).
- 486 26. Gounder PP, Koch A, Provo G, Lovlie A, Ederth JL, Axelsson M, et al. Summary of available
487 surveillance data on hepatitis C virus infection from eight Arctic countries, 2012 to 2014. *Euro Surveill*.
488 2018;23(40).
- 489 27. America AAftSoLDaIDSo. HCV Guidance: Recommendations for Testing, Managing, and Treating
490 Hepatitis C 2014-2018 [Available from: hcvguidelines.org.
- 491 28. AASLD. AASLD guidelines for treatment of chronic hepatitis B 2015 [Available from:
492 <https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.28156>.
- 493 29. Gayam V, Tionson B, Khalid M, Mandal AK, Mukhtar O, Gill A, et al. Sofosbuvir based regimens
494 in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-
495 based retrospective cohort study. *Eur J Gastroenterol Hepatol*. 2018;30(10):1200-7.
- 496 30. Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the
497 effectiveness of direct antiviral agents for hepatitis C virus infection. *Hepatology*. 2017;65(2):426-38.
- 498 31. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and
499 ribavirin in HCV genotypes 2 and 3. *N Engl J Med*. 2014;370(21):1993-2001.
- 500 32. Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, et al. Treatment with
501 ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3
502 clinical trials. *Hepatology*. 2015;61(6):1798-808.
- 503 33. Esteban R, Pineda JA, Calleja JL, Casado M, Rodriguez M, Turnes J, et al. Efficacy of Sofosbuvir
504 and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and
505 Cirrhosis. *Gastroenterology*. 2018;155(4):1120-7 e4.
- 506 34. Alonso S, Riveiro-Barciela M, Fernandez I, Rincon D, Real Y, Llerena S, et al. Effectiveness and
507 safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection
508 and cirrhosis. Results of a multicenter real-life cohort. *J Viral Hepat*. 2017;24(4):304-11.
- 509 35. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment
510 with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III
511 study. *Hepatology*. 2015;61(4):1127-35.
- 512 36. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and
513 ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-
514 3+). *Hepatology*. 2016;63(5):1430-41.
- 515 37. Sung JC, Bosh C, Wyatt B, Miller M, Harty A, Del Bello D, et al. Hepatitis C cure improved patient-
516 reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban
517 medical center. *J Viral Hepat*. 2019.

- 518 38. Lledo GM, Carrasco I, Benitez-Gutierrez LM, Arias A, Royuela A, Requena S, et al. Regression of
519 liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV
520 coinfection. *AIDS*. 2018;32(16):2347-52.
- 521 39. Zeng X, Xu C, He D, Zhang H, Xia J, Shi D, et al. Influence of Hepatic Inflammation on FibroScan
522 Findings in Diagnosing Fibrosis in Patients with Chronic Hepatitis B. *Ultrasound Med Biol*.
523 2015;41(6):1538-44.
- 524 40. Loggi E, Gitto S, Galli S, Minichiello M, Conti F, Grandini E, et al. Hepatitis B virus reactivation
525 among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. *J Clin*
526 *Viro*. 2017;93:66-70.
- 527 41. Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM, et al. Effectiveness and Safety of
528 Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.
529 *Clin Infect Dis*. 2016;63(6):776-83.
- 530 42. Younossi ZM, Park H, Gordon SC, Ferguson JR, Ahmed A, Dieterich D, et al. Real-world outcomes
531 of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. *Am J Manag Care*. 2016;22(6 Spec
532 No.):SP205-11.
- 533 43. Lawitz E, Poordad F, Gutierrez JA, Kakuda TN, Picchio G, Beets G, et al. Simeprevir, daclatasvir
534 and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease. *J Viral Hepat*.
535 2017;24(4):287-94.
- 536 44. Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES. An HCV-positive recipient of
537 an HCV-positive donor liver successfully treated before and immediately after liver transplant with
538 daclatasvir, sofosbuvir, and ribavirin. *Clin Case Rep*. 2017;5(4):371-5.
- 539 45. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and
540 dasabuvir with ribavirin for hepatitis C with cirrhosis. *N Engl J Med*. 2014;370(21):1973-82.
- 541 46. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, et al. Ledipasvir
542 and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and
543 previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3
544 trial. *Lancet Infect Dis*. 2015;15(6):645-53.
- 545 47. Mera J, Joshi K, Thornton K, Box T, Scott J, Sedillo M, et al. Retrospective Study Demonstrating
546 High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among
547 American Indian/Alaskan Natives. *Open Forum Infect Dis*. 2019;6(7):ofz128.
- 548 48. Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a
549 systematic review of the clinical, economic and quality of life benefits. *BMC Infect Dis*. 2015;15:19.
- 550 49. El Khoury AC, Klimack WK, Wallace C, Razavi H. Economic burden of hepatitis C-associated
551 diseases in the United States. *J Viral Hepat*. 2012;19(3):153-60.

552

553

554 Table 1. Treatment Regimens of 501 AN/AI persons treated for hepatitis C in Alaska using
 555 sofosbuvir-based Direct Acting Antiviral therapy, Alaska (2014-2018).

Treatment Regimen	Duration of treatment and sample size	Indication
Ledipasvir/sofosbuvir	8 weeks (n =110)	GT 1 without cirrhosis and HCV viral load < 6 million international units/mL could be given for a shortened course of 8 weeks, in accordance with prescribing information and at the discretion of the prescribing provider
Ledipasvir/sofosbuvir	12 weeks (n =238)	GT 1,4,5,and 6 patients who were treatment naïve without cirrhosis or with compensated cirrhosis or GT 1,4,5, and 6 patients without cirrhosis who had previously been treated with interferon-based treatment
Sofosbuvir plus ribavirin	12 weeks (n = 39)	GT 2 without cirrhosis. Used until sofosbuvir/velpatasvir became available in Aug 2016
Sofosbuvir plus ribavirin	16 weeks (n = 6)	GT 2 with cirrhosis or previously treated with interferon-based treatment. Used until sofosbuvir/velpatasvir became available in Aug 2016
Sofosbuvir plus ribavirin	24 weeks (n = 14)	GT 3 regardless of cirrhosis status. Used until sofosbuvir/velpatasvir became available in Aug 2016
Sofosbuvir/velpatasvir	12 weeks (n = 94)	All GTs without cirrhosis or with compensated cirrhosis starting in Aug 2016

556

557

558 Table 2. Characteristics of 501 AN/AI persons treated for hepatitis C in Alaska using sofosbuvir-
559 based DAA therapy, Alaska (2014-2018).

Characteristic	Level	All Persons % (n = 501)	Persons Treated at ANMC % (n = 378)
Treatment Location	ANMC	75% (378)	100% (378)
	Non-ANMC	25% (123)	
Completed Therapy		96% (482)	95% (360)
Previously treated		5% (27)	6% (22)
IL28b (n= 326)	CC	45% (145)	45% (120)
	CT	46% (151)	46% (124)
	TT	9% (30)	9% (25)
Known HIV Positive		2% (8)	1% (5)
Treatment Length	8 Weeks	22% (109)	22% (84)
	12 Weeks	74% (372)	74% (279)
	16 Weeks	1% (6)	1% (4)
	24 Weeks	3% (14)	3% (11)
Treatment Regimen	Sofosbuvir+Ribavirin	12% (59)	12% (45)
	Ledipasvir/Sofosbuvir	70% (348)	67% (252)
	Sofosbuvir/Velpatasvir	18% (94)	21% (81)
HCV GT	1a	65% (327)	64% (242)
	1b	10% (52)	10% (39)
	2	15% (75)	16% (59)
	3	9% (45)	10% (37)
	4, 6	0.4% (1 each)	0.3% (1 GT 6)
Female Gender		46% (229)	47% (177)
PPI/Antacid Use ^a		29% (96/335)	29% (95/331)
Characteristics at Start of Treatment			
Median Age (range)		54.3 Years (21.3,	52.3 years (22.3, 72.7)
Mean BMI		28.0	28.1
% BMI ≥ 30		29% (122/417)	30% (106/356)
Advanced Fibrosis (F3-F4)		27% (134/497)	22% (84)
Cirrhosis (F4)		14% (69/497)	13% (49)
Median ALT (min, max) at		52 (7, 612)	51 (7, 612)
HCV RNA ≥ 6 million ^b		18% (92)	20% (76/378)
Vitamin D < 30 iu/mL ^b		45% (185/415)	45% (153/341)
Vitamin D < 20 iu/mL ^b		15% (64/415)	15% (50/341)
Mean A1C % (min, max) ^b		5.6 (4.4, 11.6)	5.4 (4.4, 11.6)
Median AFP ^b		3.6 (0.6, 226.1)	3.4 (0.6, 226.1)
Median GFR (mL/min) ^b		94 (38, 257)	98 (38, 257)
Positive Anti-HBc ^c Start		20% (93/460)	19% (67/360)

560 ^a – Defined as use of any PPI, H2 blocker, or magnesium or aluminum containing antacid.

561 ^b – These labs were collected between 24 weeks prior to treatment start until one week after treatment start. The closest
562 chronologically to the treatment start date was used in calculation of mean or median.

563 ^c – At any time point prior to treatment

555 Table 3. Treatment success results among AN/AI (sustained virologic response at 12 weeks post
566 treatment) by Intention-to-treat and Per-protocol Analyses with 95% Confidence Intervals [CI],
567 Alaska, 2014-2018

Category	Level	SVR Intention-to-treat	P-value for Difference	SVR Per-protocol ^a	P-value for Difference
Overall		95.2% [93.3, 97.1]		97.3% [95.8, 98.7]	
Sex	Female	96.9% [93.8, 98.8]	0.09	98.2% [95.4, 99.5]	0.26
	Male	93.8% [90.9, 96.6]		96.5% [94.3, 98.8]	
Age	< 40 years	93.3% [89.7, 98.7]	0.95	99.0% [94.3, 99.9]	0.18
	40-59 years	95.9% [93.6, 98.3]		97.3% [95.3, 99.3]	
	≥ 60 years	94.5% [90.6, 98.5]		96.0% [92.5, 99.4]	
Birth Cohort	Pre 1966	95.0% [92.6, 97.4]	0.75	96.4% [94.3, 98.5]	0.15
	After 1966	95.6% [92.6, 98.6]		98.8% [95.9, 99.9]	
Treatment Location	ANMC	95.8% [93.7, 97.8]	0.32	98.3% [96.4, 99.4]	0.02
	Rural	93.5% [89.1, 97.9]		94.2% [88.4, 97.6]	
Completed Treatment	Yes	97.9% [96.0, 99.1]	<0.0001	Not Applicable	
	No	54.6% [32.2, 75.6]		Not Applicable	
Treatment Regimen	Led/Sof ^b	96.8% [95.0, 98.7]	0.004 ^c	97.9% [96.4, 99.4] ^d	0.01 ^c
	Sof/Riba	86.4% [77.7, 95.2]		90.6% [82.7, 98.4]	
	Sof/Vel	94.6% [88.0, 98.3]		98.9% [94.0, 100.0]	
BMI ≥ 30	Yes	92.6% [88.0, 97.3]	0.13	94.0% [89.7, 98.3]	0.02
	No	96.3% [94.1, 98.4]		98.6% [96.4, 99.6]	
Steatosis (CAP > 248)	Yes	92.8% [88.7, 96.9]	0.09	94.6% [91.0, 98.2]	0.05
	No	97.0% [94.3, 99.6]		98.7% [99.5, 99.9]	
A1c ≥ 5.7	Yes	94.6% [86.7, 98.5]	0.76	97.2% [90.3, 99.7]	1.00
	No	95.5% [93.1, 97.9]		97.8% [96.0, 99.5]	
Hep B Core + ^e	Yes	93.6% [88.6, 98.5]	0.40	93.3% [88.2, 98.5]	0.08
	No	95.9% [93.9, 97.9]		98.3% [96.9, 99.7]	
Fibrosis Level	F0-F1	96.1% [93.9, 98.4]	0.13	99.3% [97.4, 99.9]	0.002 ^f
	F2	96.2% [89.2, 99.2]		97.4% [90.8, 99.7]	
	F3	92.3% [83.0, 97.5]		93.4% [84.1, 98.2]	
	F4	92.8% [83.9, 97.6]		92.7% [83.7, 97.6]	
HCV GT	1a	95.1% [92.7, 97.4]	0.14	97.4% [95.0, 98.9]	0.38
	1b	100.0% [93.2, 100.0]		100.0% [93.0, 100.0]	
	2	94.7% [86.9, 98.5]		95.9% [88.5, 99.1]	
	3	91.1% [78.8, 97.5]		95.1% [83.5, 99.4]	
HCV RNA Level	≥ 6 million	92.4% [87.0, 97.8]	0.28	95.4% [88.5, 98.7]	0.26
	< 6 million	95.8% [93.9, 97.8]		97.7% [96.2, 99.2]	
IL-28b	CC	97.9% [94.1, 99.6]	0.22	98.6% [95.0, 99.8]	0.15
	CT	94.0% [90.3, 97.8]		95.2% [91.7, 98.7]	

	TT	93.3% [77.9, 99.2]		100.0% [87.2, 100.0]	
Compensated Cirrhosis	Yes	92.8% [83.9, 97.6]	0.36	92.7% [83.7, 97.6]	0.03
	No	95.6% [93.6, 97.5]		98.0% [96.7, 99.4]	
PPI Use ^g	Yes	92.5% [83.4, 97.5]	0.35	96.8% [89.0, 99.6]	0.68
	No	95.6% [93.7, 97.6]		97.4% [95.8, 98.9]	
Treatment Naive	Yes	95.6% [93.7, 97.4]	0.13	97.8% [96.4, 99.2]	0.03
	No	88.9% [70.8, 97.7]		88.5% [69.9, 97.6]	

568 ^a – Persons Discontinuing Treatment Were Removed and Persons with Unknown SVR

569 ^b – *P*-value for Ledsof 8-week (99.1%, 108/109) vs. Ledsof 12-week (95.8%, 229/239) treatment = 0.18

570 ^c – *P*-value is for Led/Sof and Sof/Vel vs. Sof/Riba

571 ^d – *P*-value for Ledsof 8-week (99.1%, 108/109) vs. Ledsof 12-week (97.4%, 221/227) treatment = 0.44

572 ^e – all 4 persons who were positive for HBsAg responded with an SVR at 12 weeks

573 ^f – *P*-value for F0-F1-F2 vs. F3-F4 :

574 ^g – 67 persons with omeprazole

575

576

577 Table 4. Changes in Fibrosis Markers Among AN/AI Pre and Post Treatment for Persons ^a
 578 Treated with Sofosbuvir-Based DAAs at ANMC^b, Alaska, 2014-2018.

Variable	Cohort	Pre Treatment ^c	Post Treatment ^d	P-value	Post Treatment 2 ^e
Median ALT ^f	Among All	51.0 (7, 612) (n = 379)	16.0 (4, 120) (n = 334)	< 0.0001	
	Success SVR	51.0 (7, 612) (n = 352)	16.0 (4, 120) (n = 313)	< 0.0001	
Median AFP ^g	Among All	3.4 (0.6, 226.1) (n = 378)	3.0 (0.9, 440.7) (n = 283)	< 0.0001	
	Success SVR	3.4 (0.6, 87.9) (n = 351)	3.0 (0.9, 440.7) (n = 265)	< 0.0001	
Median AFP (Among All)	F0-F1	3.0 (0.6, 14.1) (n = 240)	2.8 (1.0, 14.4) (n = 177)	0.0004	
	F2	3.5 (0.7, 22.5) (n = 54)	3.2 (0.9, 9.4) (n = 39)	0.008	
	F3-F4	6.3 (1.7, 226.1) (n = 84)	3.7 (1.6, 440.7) (n = 67)	<0.0001	
Median AFP (Among those who achieved SVR)	F0-F1	3.0 (0.6, 14.1) (n = 223)	2.7 (1.0, 14.4) (n = 167)	<0.0001	
	F2	3.5 (0.7, 22.5) (n = 52)	3.2 (0.9, 9.4) (n = 38)	0.005	
	F3-F4	6.3 (1.7, 87.9) (n = 76)	3.6 (1.6, 440.7) (n = 60)	<0.0001	
VCTE ^h	Among All	5.7 (2.3, 46.4) (n = 308)	5.1 (2.3, 75.0) (n = 291)	<0.0001	
	Success SVR	5.8 (2.3, 46.4) (n = 289)	5.1 (2.3, 75.0) (n = 283)	0.02	5.0 (2.7, 48) (n = 209)
VCTE (Among All)	F0-F1	5.1 (2.3, 10.4) (n = 200)	4.6 (2.3, 21.3) (n = 180)	0.03	
	F2	7.6 (3.0, 12.5) (n = 49)	5.3 (2.7, 12.1) (n = 45)	<0.0001	
	F3-F4	11.9 (4.5, 46.4) (n = 59)	9.4 (3.3, 75.0) (n = 66)	<0.0001	
VCTE (Among those who achieved SVR)	F0-F1	5.1 (2.3, 7.9) (n = 186)	4.6 (2.3, 21.3) (n = 175)	0.03	4.6 (2.7, 19.0) (n = 125)
	F2	7.6 (3.0, 12.5) (n = 47)	5.3 (2.7, 12.1) (n = 45)	<0.0001	4.6 (2.9, 9.5) (n = 27)
	F3-F4	12.1 (4.5, 46.4) (n = 56)	8.8 (3.3, 75.0) (n = 63)	<0.0001	7.4 (4.1, 48.0) (n = 57)

579 ^a - n=378
 580 ^b - Alaska Native Medical Center
 581 ^c - from 6 weeks prior to treatment start to 1 week after treatment start
 582 ^d - from 12-36 weeks after treatment stopped
 583 ^e - from 1 years to < 2 years post therapy
 584 ^f - ALT = alanine aminotransferase
 585 ^g - AFP = alpha fetoprotein
 586 ^h - VCTE = vibration controlled transient elastography

587 Table 5. Symptoms Experienced According to Hepatitis C Treatment Regimen among an Alaska
 588 Native/American Indian Cohort^a 2014-2018,
 589

Side Effect ^b	Treatment Week	Drug Regimen		
		Sofosbuvir/Ribavirin (n = 45)	Ledipasvir/Sofosbuvir (n = 252)	Sofosbuvir/Velpatasvir (n = 81)
Tired	0	41% (18/44)	35% (87/246)	51% (37/73)
	End of Treatment	41% (15/37)	33% (73/221)	43% (30/69)
P-value		0.95	0.54	0.37
Headache	0	16% (7/44)	26% (64/246)	25% (18/73)
	End of Treatment	22% (8/37)	36% (79/221)	25% (17/69)
P-value		0.24	0.004 ↑	0.86
Trouble Sleeping	0	36% (16/44)	43% (106/246)	42% (31/73)
	End of Treatment	49% (18/37)	35% (78/221)	38% (26/69)
P-value		0.38	0.02 ↓	0.58
Joint Pain	0	52% (23/44)	44% (109/246)	51% (37/73)
	End of Treatment	27% (10/37)	32% (70/221)	38% (26/69)
P-value		0.009 ↓	0.001 ↓	0.04 ↓
Back Pain	0	45% (20/27)	44% (107/246)	55% (40/73)
	End of Treatment	22% (8/37)	33% (72/221)	42% (29/69)
P-value		0.01 ↓	0.002 ↓	0.06
Muscle Pain	0	32% (14/44)	39% (96/246)	42% (31/73)
	End of Treatment	24% (9/37)	31% (69/221)	33% (23/69)
P-value		0.27	0.04 ↓	0.21
Forgetful	0	23% (10/44)	31% (76/246)	32% (23/73)
	End of Treatment	32% (12/37)	25% (56/221)	28% (19/69)
P-value		0.30	0.12	0.64
Dry Mouth	0	18% (8/44)	24% (59/246)	15% (11/73)
	End of Treatment	24% (9/37)	24% (54/221)	22% (15/69)
P-value		0.39	0.76	0.14
Weakness	0	9% (4/44)	18% (45/246)	30% (22/73)
	End of Treatment	24% (9/37)	21% (46/221)	26% (18/69)

P-value		0.08	0.36	0.64
Irritability	0	16% (7/44)	16% (39/246)	21% (15/73)
	End of Treatment	32% (12/37)	15% (34/221)	16% (11/69)
P-value		0.09	0.86	0.44
Depression	0	11% (5/44)	25% (62/246)	34% (25/73)
	End of Treatment	24% (9/37)	21% (46/221)	22% (15/69)
P-value		0.06	0.23	0.02 ↓
Itching	0	14% (6/44)	15% (38/246)	19% (14/73)
	End of Treatment	27% (10/37)	14% (30/221)	19% (13/69)
P-value		0.10	0.32	0.98
Changes in Mood	0	14% (6/44)	17% (42/246)	23% (17/73)
	End of Treatment	30% (11/37)	17% (38/221)	16% (11/69)
P-value		0.04 ↑	0.92	0.27
Heartburn	0	11% (5/44)	21% (52/246)	26% (19/73)
	End of Treatment	19% (7/37)	19% (42/221)	23% (16/69)
P-value		0.34	0.43	0.60
Shortness of Breath	0	7% (4/44)	14% (34/246)	30% (22/73)
	End of Treatment	35% (13/37)	14% (30/221)	22% (15/69)
P-value		0.003 ↑	0.95	0.15
Nausea	0	5% (2/44)	11% (26/246)	22% (16/73)
	End of Treatment	8% (3/37)	16% (35/221)	28% (19/69)
P-value		0.48	0.05	0.41
Blurred Vision	0	16% (7/44)	18% (44/246)	21% (15/73)
	End of Treatment	19% (7/37)	15% (34/221)	15% (10/69)
P-value		0.71	0.42	0.36
Decreased Appetite	0	9% (4/44)	13% (32/246)	25% (18/73)
	End of Treatment	14% (5/37)	13% (29/221)	9% (6/69)
P-value		0.53	0.97	0.009 ↓
Diarrhea	0	5% (2/44)	8% (19/246)	14% (10/73)
	End of Treatment	14% (5/37)	11% (24/221)	13% (9/69)

P-value		0.08	0.21	0.95
Cough	0	9% (4/44)	15% (36/246)	21% (15/73)
	End of Treatment	16% (6/37)	12% (27/221)	20% (14/69)
P-value		0.32	0.43	0.95
Chills	0	2% (1/44)	9% (23/246)	15% (11/73)
	End of Treatment	16% (6/37)	11% (25/221)	23% (16/69)
P-value		0.06	0.46	0.17
Dizziness	0	2% (1/44)	9% (23/246)	22% (16/73)
	End of Treatment	19% (7/37)	10% (22/221)	12% (8/69)
P-value		0.04 ↑	0.86	0.09
Flu-Like Symptoms	0	9% (4/44)	7% (16/246)	11% (8/73)
	End of Treatment	5% (2/37)	11% (25/221)	17% (12/69)
P-value		0.43	0.05	0.21
Rash	0	11% (5/44)	8% (20/246)	12% (9/73)
	End of Treatment	15% (6/37)	7% (16/221)	10% (7/69)
P-value		0.44	0.65	0.83
Hair Loss	0	5% (2/44)	6% (15/246)	12% (9/73)
	End of Treatment	8% (3/37)	10% (23/221)	17% (12/69)
P-value		0.49	0.07	0.33
Vomiting	0	5% (2/44)	4% (10/246)	7% (5/73)
	End of Treatment	3% (1/37)	3% (7/221)	6% (4/69)
P-value		0.68	0.48	0.77
Anemia	0	0% (0/44)	0% (0/246)	1% (1/73)
	End of Treatment	3% (1/37)	3% (6/221)	0% (0/69)
P-value		Not tested	Not tested	Not tested
Fever	0	0% (0/44)	3% (8/246)	7% (5/73)
	End of Treatment	0% (0/37)	5% (12/221)	7% (5/69)
P-value		Not tested	0.24	0.93

^a – statistically significant P-value change shown in bold with arrow to indicate increase (↑) or decrease (↓) in symptom

^b - data collected on 33 symptoms

590
591
592
593